96 related articles for article (PubMed ID: 16078851)
1. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
[TBL] [Abstract][Full Text] [Related]
2. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
[TBL] [Abstract][Full Text] [Related]
4. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor.
Dissoki S; Aviv Y; Laky D; Abourbeh G; Levitzki A; Mishani E
Appl Radiat Isot; 2007 Oct; 65(10):1140-51. PubMed ID: 17574425
[TBL] [Abstract][Full Text] [Related]
5. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035.
Wang H; Yu JM; Yang GR; Song XR; Sun XR; Zhao SQ; Wang XW; Zhao W
Chin Med J (Engl); 2007 Jun; 120(11):960-4. PubMed ID: 17624262
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
[TBL] [Abstract][Full Text] [Related]
8. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M
Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817
[TBL] [Abstract][Full Text] [Related]
9. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
11. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
Hennequin LF; Ballard P; Boyle FT; Delouvrié B; Ellston RP; Halsall CT; Harris CS; Hudson K; Kendrew J; Pease JE; Ross HS; Smith P; Vincent JL
Bioorg Med Chem Lett; 2006 May; 16(10):2672-6. PubMed ID: 16516473
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors.
Bettio A; Honer M; Müller C; Brühlmeier M; Müller U; Schibli R; Groehn V; Schubiger AP; Ametamey SM
J Nucl Med; 2006 Jul; 47(7):1153-60. PubMed ID: 16818950
[TBL] [Abstract][Full Text] [Related]
15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
16. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
[TBL] [Abstract][Full Text] [Related]
17. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
VanBrocklin HF; Lim JK; Coffing SL; Hom DL; Negash K; Ono MY; Gilmore JL; Bryant I; Riese DJ
J Med Chem; 2005 Nov; 48(23):7445-56. PubMed ID: 16279804
[TBL] [Abstract][Full Text] [Related]
18. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
19. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
[TBL] [Abstract][Full Text] [Related]
20. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
